• Roby Zomer appointed Managing Director to implement
the Board’s strategy across the Pharma, Botanic and
Derma divisions. Nativ Segev remains a Director and
becomes Head of Business Strategy to drive sales and
secure additional distribution pipelines for MXC
• $5m raised via oversubscribed share placement
to sophisticated and professional investors and
strategic funds, to help establish the Company’s
Maltese medical cannabis production and cultivation
facility and for general working capital
Pharma division
Full Good Manufacturing Practice (GMP) Certication
and manufacturing licence received for MXC’s European
production and manufacturing facility in Slovenia,
representing a landmark for the Company which now
has one of the most advanced facilities in Europe
• First batch of CannEpilTM completed and to
undergo one nal assessment before commercial
sales and distribution can commence
• Malta Enterprise Corporation granted approval and a
contract to establish a medical cannabis facility on the
4000m2 of land designated to MXC which demonstrates
the agenda of seed-to-pharma operations
• Supply agreements signed with specialist pharmaceutical
distributors - HL Pharma in Australia, MW Pharma
in New Zealand and Lenis in Europe, paving the
way for high revenue generation and expedited
distribution of MXC’s pharmaceutical products
• Research projects with RMIT advanced, with library
of cannabinoids established and the research team
expanded to explore the properties and uses of
medical cannabis in real-life applications
Botanic division
Czech Republic’s rst crop achieves major milestone as
cannabidiol is successfully extracted from harvested owers
for use in the production of the Nutraceuticals and Derma
ranges, demonstrating the Company’s seed-to-sale operations
The second Czech Republic crop planted in
early Q2 2018 and has reached vegetation
stage, with harvest expected in Q3 2018
• Genetic research programme at the University of Ljubljana
delivers positive results as MXC successfully produces owers
of specic genders and varying levels of CBD and THC content
Derma division
Two new research backed and scientically
engineered products launched; the CBD Herbal
Replenish Cream and CBD Herbal Repair Cream both
targeting oily, itchy, aky and acne prone skin
First signicant MGC Derma supply agreements signed
with leading retailers Cult Beauty and Harvey Nichols
to sell MXC’s MGC Derma and Derma Plus ranges
internationally, strengthening the brands exposure
Review of
Review of Operations